RE: Reading the last outlook7 May 2017 11:32
Hi unv, businesses like this most certainly get bought out and I expect that one day, one of the bigger diagnostics players such as Roche, will snap this up. But not for a while yet. I think it more likely to happen once we are fully commercialised with Visitect CD4 etc.
I certainly agree that this business is going to grow substantially in the next two years. The accelerated growth will translate into a rerating, higher PE ratio etc. More institutional buying will occur.
As regards Malaria they've signalled to the market that sales will grow more quickly in the next financial year. I'm sure they said they were developing a pregnancy test too?
The Finn cap 28p target takes no account of CD4 sales(!) since there is no visibility on that yet so goodness knows what the the upgrade will be once there is! I look forward to it ;)
Good weekend :)